Fidelity Investments
CARM

Fidelity Investments’s Carisma Therapeutics CARM Stock Holding History

Fidelity Investments’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-736
Closed -$722 – 5581
2024
Q3 		$722 Sell
736
-35,109
-98% -$38K ﹤0.01% 4939
2024
Q2 		$54.5K Buy
35,845
+11,832
+49% +$17.6K ﹤0.01% 3568
2024
Q1 		$54.5K Sell
24,013
-745
-3% -$1.79K ﹤0.01% 3547
2023
Q4 		$72.5K Sell
24,758
-3,936
-14% -$11.7K ﹤0.01% 3352
2023
Q3 		$121K Buy
28,694
+215
+0.8% +$1.36K ﹤0.01% 3038
2023
Q2 		$250K Buy
28,479
+4,708
+20% +$25.6K ﹤0.01% 2884
2023
Q1 		$73.7K Buy
23,771
+252
+1% +$2.4K ﹤0.01% 3297
2022
Q4 		$287K Sell
23,519
-273
-1% -$2.87K ﹤0.01% 2900
2022
Q3 		$202K Sell
23,792
-1,858
-7% -$25.3K ﹤0.01% 3047
2022
Q2 		$416K Sell
25,650
-8,539
-25% -$97.7K ﹤0.01% 2902
2022
Q1 		$412K Buy
+34,189
New +$478K ﹤0.01% 3047
2021
Q4 		– Sell
-8
Closed – – 4375
2021
Q3 		$0 Buy
+8
New +$384 ﹤0.01% 4392
2021
Q2 		– Hold
0
– – – 4285
2016
Q1 		– Sell
-143,180
Closed -$8.62M – 2671
2015
Q4 		$8.62M Sell
143,180
-690
-0.5% -$39.2K ﹤0.01% 2041
2015
Q3 		$6.93M Hold
143,870
– – ﹤0.01% 2074
2015
Q2 		$8.11M Buy
143,870
+55,614
+63% +$7.85M ﹤0.01% 2095
2015
Q1 		$15.7M Hold
88,256
– – ﹤0.01% 1828
2014
Q4 		$21M Sell
88,256
-2,940
-3% -$659K ﹤0.01% 1707
2014
Q3 		$20.3M Sell
91,196
-180
-0.2% -$42.8K ﹤0.01% 1726
2014
Q2 		$24.1M Buy
91,376
+10,640
+13% +$2.63M ﹤0.01% 1710
2014
Q1 		$26.2M Buy
+80,736
New +$24.2M ﹤0.01% 1645

Other funds holding CARM

MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelity Investments's CARM Position: Q4 2024 in Review

Fidelity Investments sold out of Carisma Therapeutics (CARM) in Q4 2024, closing a stake of 736 shares — an estimated $722 sold.

Fidelity Investments first reported a position in CARM in Q1 2014 and held it in 20 quarters. The position peaked at $26.2M in Q1 2014. 41 funds tracked by Wall St. Rank hold CARM as of Q4 2024.

  • Fidelity Investments reported no remaining Carisma Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fidelity Investments sold 736 Carisma Therapeutics shares in Q4 2024, an estimated $722.
  • Fidelity Investments first reported a position in Carisma Therapeutics in Q1 2014 and held it in 20 quarters.
  • Fidelity Investments's Carisma Therapeutics position peaked at $26.2M in Q1 2014.
  • 41 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2024.

Based on Fidelity Investments's 13F filing for Q4 2024, filed 13 Feb 2025.